Valneva (VALN) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

VALN Valneva

Watchlist

3.930
+0.000+0.00%

Close Dec 13 16:00 ET

319.06MMarket Cap-31.19P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

VALNEVA - Declaration of Shares and Voting Rights: November 30, 2024
GlobeNewswireDec 5 01:30 ET
Valneva Highlights Chikungunya's Global Economic Impact
TipRanksDec 4 12:28 ET
Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal
GlobeNewswireDec 4 01:00 ET
Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults
BenzingaDec 3 11:41 ET
Valneva Reports Positive Three-Year Antibody Persistence Data for Its Single-Shot Chikungunya Vaccine IXCHIQ
GlobeNewswireDec 3 01:00 ET
Valneva Seeks US FDA Nod for Label Extension of Chikungunya Vaccine
MT NewswiresNov 26 23:54 ET

Comments

Trytosaveabit

Nov 26 11:05

Watching

$Valneva (VALN.US)$ Valneva Submits Label Extension Application For Its Chikungunya Vaccine, IXCHIQ, To The U.S. FDA To Potentially Include Adolescents And Antibody Persistence Up To 2-Years

Chad Dunbar

Oct 31 14:42

Vaccine that nobody is talking about has potential…

$Valneva (VALN.US)$
I notice that when people talk about Valneva, you hear endless talk about Lyme & Chikungunya, but there is almost no talk about SV4, a tetravalent bioconjugate vaccine candidate against shigellosis that is entering Phase 2. It seems that most of the talk regarding this centers around children in third world underdeveloped countries, but there is a possible huge market if it gets worked into the standard childhood vaccine sched...

Trytosaveabit

Sep 3 08:15

Update

$Valneva (VALN.US)$ Pfizer, Valneva Report Further Positive Phase 2 Booster Results For Lyme Disease Vaccine Candidate
Drug makers Pfizer Inc. (PFE) and Valneva SE (VALN) announced Tuesday positive immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the first booster dose.
Pfizer aims to submit a Biologics License Application or BLA to the U.S. Food and Drug Ad...

Trytosaveabit

Jul 22 05:30

News

$Valneva (VALN.US)$ Valneva is set to receive up to $41.3 million from CEPI and the EU to enhance access to IXCHIQ®, the world’s first chikungunya vaccine, particularly in low- and middle-income countries. The funding will bolster clinical trials in vulnerable groups and support technology transfer to additional manufacturers, ensuring wider distribution in regions at risk of chikungunya outbreaks. With approvals already in place in the U.S., Canada, and Europe, the company aims to extend the...